FDA Seeks Input on Improving Access to Nonprescription Medications
Published Date: 12/2/2025
Notice
Summary
The FDA wants your ideas on how to make it easier for people to get nonprescription drugs, like over-the-counter medicines. They’re gathering feedback now to help plan a public meeting in 2026. If you have thoughts, send them by February 2, 2026—this could lead to faster, cheaper access for everyone!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
NDA pathway requires consumer-use studies
If you seek to market a nonprescription drug via a new drug application (NDA) under section 505, you must submit adequate tests and substantial evidence that the drug is safe and effective for self-use. FDA often requires consumer studies—such as label comprehension, self-selection, actual use, and human factors studies—and typically requires more data when less is known about nonprescription use.
Public input open — comments due Feb 2, 2026
The FDA is asking the public—drug developers, health care providers, and consumers—to send ideas on how to increase access to nonprescription (over-the-counter) drugs. You can submit electronic or written comments that must be received by February 2, 2026; FDA will use the feedback to plan a public meeting in calendar year 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-21727, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got several filings from energy companies like Public Service Company of New Mexico and Aron Energy Prepay LLCs about updates to electric rates and company status. These changes could affect how energy prices and rules work, with some updates set to take effect as soon as May or August 2025. If you want to comment, deadlines are coming up fast in November and December 2025.
Next: 2025-21729, Records Governing Off-the-Record Communications; Public Notice
The Federal Energy Regulatory Commission (FERC) is sharing updates about off-the-record communications in ongoing cases. They remind everyone that some secret chats can’t affect decisions unless fairness calls for it, while others are part of the official record. This keeps the process fair and transparent, with no new costs or deadlines announced.